Figure 2G shows the relationships of CDK1 expression with age, sex, smoking history, tumor stage, and overall survival time for LUAD patients in the TCGA database. CDK1 was highly expressed in LUAD cases with advanced tumor-node-metastasis (TNM) stage, which was consistent with the results from the GSE31210, GSE68465, and GSE72094 datasets. (Figure 2H). Poorly differentiated tumors showed high expression of CDK1 in the GSE68465 dataset (Figure 2H). Moreover, CDK1 tended to be highly expressed in tumors with wild-type epidermal growth factor receptor (EGFR) and TP53 mutation (Figure 2H). This evidence concerns the gene CDK1 and neoplasm.